logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Kymab Limited


USPTO Granted Patents = 111

% Expired Patents = 0.9


Trademarks = 2

Forward Citations = 1,007

Loading Chart...
Loading Chart...

85 inventors (with patents filed for the assignee):

goldMedal Jasper Clube (54 out of 55 patents)

silverMedal E-Chiang Lee (43 out of 43 patents)

bronzeMedal Allan Bradley (33 out of 47 patents)

4.  Qi Liang (24 out of 24 patents)

5.  Wei Wang (23 out of 40 patents)

6.  Ian Kirby (23 out of 28 patents)

7.  Jamie Iain Campbell (23 out of 27 patents)

8.  Miha Kosmac (22 out of 22 patents)

9.  Steve Holmes (16 out of 28 patents)

10.  Hui Liu (12 out of 12 patents)

11.  Volker Germaschewski (12 out of 12 patents)

12.  Dominik Spensberger (11 out of 11 patents)

13.  Glenn A Friedrich (10 out of 54 patents)

14.  Cassandra Van Krinks (8 out of 8 patents)

15.  Thomas Gallagher (7 out of 7 patents)


Core Competencies:
Antibody
Biologics
Bispecific Antibodies
Immunotherapy
Precision Medicine
Graft Versus Host Disease
Cholesterol Treatment
Transgenic Models
Human Antibodies
Cancer Treatment
Neurodegenerative Diseases
Iron Overload

111 patents:

1. 12723104 - IMPROVED LAMBDA ANTIBODIES (2026-09-01),
2. 12703754 - TREATMENT OF ATOPIC DERMATITIS (2026-08-11),
3. 12698323 - ANTAGONISTS (2026-08-04),
4. 12696885 - CELLS, VERTEBRATES, POPULATIONS & METHODS (2026-08-04),
5. RE50880 - Anti-Human OX40L Antibodies and Methods of Treatment (2026-05-05),
6. 12570740 - Treatment for physiological iron overload with an anti-matriptase-2 antibody (2026-03-10),
7. 12473378 - ANTIGEN-BINDING MOLECULES COMPRISING UNPAIRED VARIABLE DOMAINS (2025-11-18),
8. 12473371 - ANTI-OPG ANTIBODIES (2025-11-18),
9. 12435134 - Antagonists anti-CD7 antibodies (2025-10-07),
10. 12404330 - Antibodies to ICOS (2025-09-02),
11. 12384855 - PCSK9 antagonists (2025-08-12),
12. 12209128 - Anti-PD-L1 antibodies (2025-01-28),
13. 11976135 - FIXaxFX bispecific antibody with common light chain (2024-05-07),
14. 11965026 - Anti-PD-L1 and IL-2 cytokines (2024-04-23),
15. 11920128 - Methods, cells and organisms (2024-03-05),
Kymab is a biotechnology company specializing in the discovery and development of fully human monoclonal antibodies. With a proprietary technology platform called Kymouse, Kymab is able to deliver a diverse and optimized pipeline of novel biologic medicines. The company collaborates with pharmaceutical partners to further advance and commercialize its therapeutic antibodies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Kymab Limited
111 Patents

#10 in Cambridge

#157 in United Kingdom

#7,097 in the World

Cambridge, GB
Cambridge, United Kingdom

Kymab Limited

Forward Citations = 1,007

85 inventors:

goldMedal Jasper Clube (54 out of 55 patents)

silverMedal E-Chiang Lee (43 out of 43 patents)

bronzeMedal Allan Bradley (33 out of 47 patents)

4.  Qi Liang (24 out of 24 patents)

5.  Wei Wang (23 out of 40 patents)

Please report any incorrect information to [email protected]
Loading…